AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 15504996
Drug: Inhaled insulin
RxNorm normalized name: insulin, regular, human Inhalation Powder [Afrezza]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled insulin (Exubera)
Trial: 11139801
Drug: Intravenous glycoprotein
RxNorm normalized name: Zaire ebolavirus envelope glycoprotein Injection [Ervebo]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous glycoprotein IIb/IIIa antagonists
Trial: 8620374
Drug: 10% carbamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% carbamide peroxide bleaching gel (2 hours exposure)
Trial: 8620374
Drug: 10% carbamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% carbamide peroxide bleaching gel (7 hours exposure)
Trial: 30417697
Drug: Expedited therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Expedited therapy
Trial: 30399122
Drug: Naloxone 8
RxNorm normalized name: naloxone 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone 8 mg
Trial: 23334070
Drug: 0.1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg/kg ponezumab
Trial: 23334070
Drug: 0.3 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg/kg ponezumab
Trial: 23334070
Drug: 1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/kg ponezumab
Trial: 23334070
Drug: 3 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg/kg ponezumab
Trial: 23334070
Drug: 10 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/kg ponezumab
Trial: 22334928
Drug: sinuforte (1.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sinuforte (1.3 mg per procedure, once daily for 7 days)
Trial: 12642739
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg twice daily for 1 week, azithromycin 500 mg/d for 3 days, amoxicillin 1 g twice daily for 1 week (OAzAm group, n = 80)
Trial: 12642739
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg twice daily for 1 week, azithromycin 500 mg/d for 3 days, tinidazole 500 mg twice daily for 3 days (OAzT group, n = 80)
Trial: 10699899
Drug: Pamidronate (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamidronate (90 mg intravenous infusion every 3-4 weeks)
Trial: 9524466
Drug: Amine fluoride
RxNorm normalized name: triethylene amine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amine fluoride (AmF) solution containing 1% fluoride, biannual applications for 5 years
Trial: 9524466
Drug: Placebo solution,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo solution, biannual applications for 5 years
Trial: 9524466
Drug: Amine fluoride
RxNorm normalized name: triethylene amine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amine fluoride (AmF) solution containing 1% fluoride
Trial: 8105512
Drug: Famotidine (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famotidine (40 mg i.v. bolus)
Trial: 8105512
Drug: Famotidine (without
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famotidine (without hG infusion)
Trial: 3513684
Drug: Hormone withdrawal
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone withdrawal after tamoxifen
Trial: 26139093
Drug: Aerobic exercise
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aerobic exercise (30 min twice a week)
Trial: 27247226
Drug: Pembrolizumab 10
RxNorm normalized name: pembrolizumab 100 MG in 4 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 10 mg/kg intravenously every 2 weeks
Trial: 24051659
Drug: Dexamethasone (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (8 mg · d(‐1), n = 8 subjects)
Trial: 23328294
Drug: sorafenib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sorafenib plus local chemotherapeutic perfusion of cisplatin 40 mg weekly for 2 weeks
Trial: 23328294
Drug: sorafenib plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sorafenib plus local chemotherapy
Trial: 19849696
Drug: 0.06% retinyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.06% retinyl retinoate applied twice daily for 12 weeks
Trial: 19849696
Drug: 0.06% retinyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.06% retinyl retinoate applied twice daily for 8 weeks
Trial: 17855671
Drug: Idraparinux (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idraparinux (2.5 mg once-weekly for 6 months)
Trial: 17855671
Drug: Vitamin K
RxNorm normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin K antagonist (initial treatment)
Trial: 30939096
Drug: Paclitaxel (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel (80 mg/m2) with trastuzumab for 12 weeks, followed by trastuzumab for 9 months
Trial: 30422235
Drug: Lanreotide (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lanreotide (120 mg subcutaneously once every 4 weeks) in addition to standard care (n=153)
Trial: 26987626
Drug: β2‐1 Fructan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: β2‐1 Fructan supplementation (3×5 g/d)
Trial: 24206841
Drug: Paracetamol administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol administration for fever (≥37·5°C)
Trial: 24206841
Drug: Insulin administration
RxNorm normalized name: insulin administration supplies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin administration for hyperglycemia (>11 mmol/L)
Trial: 22502814
Drug: Low Level
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low Level Helium Neon (He‐Ne) Laser therapy (λ=632.8 nm, P=24 mW, ED=3.5 J/cm(2))
Trial: 22502814
Drug: Low Level
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low Level Helium Neon (He‐Ne) Laser therapy
Trial: 11835024
Drug: Bivalirudin (bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bivalirudin (bolus of 0.1 mg/kg followed by an infusion of 0.25 mg/kg/h)
Trial: 11835024
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin (bolus of 70 U/kg followed by an infusion of 15 U/kg/h)
Trial: 11198951
Drug: High-dose supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose supplements of nutrients (specific nutrients not detailed)
Trial: 2036692
Drug: Bupivacaine 0.125%
RxNorm normalized name: BUPIVACAINE 0.125%/NS INJ 250ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 0.125% and fentanyl 4 micrograms.ml‐1 (Group I)
Trial: 31122894
Drug: Eosinophil-guided therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eosinophil-guided therapy (37.5 mg of oral prednisolone daily for up to 4 days based on eosinophil count)
Trial: 31122894
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (37.5 mg of oral prednisolone daily for 4 days)
Trial: 31122894
Drug: Eosinophil-guided therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eosinophil-guided therapy
Trial: 26218727
Drug: VYC‐20L (Juvéderm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VYC‐20L (Juvéderm Voluma XC) with higher injection volumes
Trial: 26218727
Drug: VYC‐20L (Juvéderm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VYC‐20L (Juvéderm Voluma XC) with median injection volume of ≈2.0 mL
Trial: 23967286
Drug: 40 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 g/d polyphenol soy protein complex (PSPC) for 17 days
Trial: 19625744
Drug: Insulin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin (1 mU.kg(‐1).min(‐1)) and dextrose to maintain euglycemia
Trial: 19625744
Drug: Insulin, dextrose,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin, dextrose, and octreotide
Trial: 17355547
Drug: Acupuncture therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture therapy according to classical Chinese Medicine (Heidelberg Model)
Trial: 11229246
Drug: Amphotericin B
RxNorm normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amphotericin B deoxycholate (ABD), 1 mg/kg day on days 1‐20, infusion completed in 2 hours.
Trial: 11229246
Drug: Escalating dose
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escalating dose of ABD (0.05 mg/kg, 0.1 mg/kg, 0.25 mg/kg, 0.5 mg/kg, 1 mg/kg on days 1‐5, then same dosage on alternate days), infusion completed in 6 hours.
Trial: 7566302
Drug: Activated powdered
RxNorm normalized name: collagen,activated Topical Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activated powdered charcoal (6 g daily p.o.)
Trial: 2231839
Drug: Maloprim (pyrimethamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maloprim (pyrimethamine and dapsone) administered fortnightly by village health workers (VHWs)
Trial: 688736
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg spironolactone per day (low dose)
Trial: 688736
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg spironolactone per day (high dose)
Trial: 21122419
Drug: NP/GP scheme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NP/GP scheme synchronization chemotherapy combined with (125)I seed implantation brachytherapy
Trial: 21122419
Drug: NP/GP scheme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NP/GP scheme chemotherapy
Trial: 15717462
Drug: Ketamine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (1 mg x kg(‐1) bolus before incision, followed by continuous infusion of 1 mg x kg(‐1) x hr(‐1) during surgery)
Trial: 15717462
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no ketamine administration)
Trial: 12501020
Drug: Injection activity
RxNorm normalized name: eptacog alfa activated Injection [Novoseven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection activity adjustment
Trial: 8877156
Drug: Oral cetirizine
RxNorm normalized name: cetirizine Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cetirizine (15 mg twice daily for 3 days)
Trial: 8877156
Drug: Inhaled beclomethasone
RxNorm normalized name: beclomethasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled beclomethasone (single dose 10 min prior to allergen challenge)
Trial: 31188064
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ADC ratio and ER
Trial: 23944632
Drug: Statins (Atorvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statins (Atorvastatin and Rosuvastatin)
Trial: 16461248
Drug: Inhalation of
RxNorm normalized name: Ocean brand of sodium chloride Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation of 2 mL tea catechin extract solution (3.7 mg/mL catechins, 43% epigallocatechin gallate) 3 times daily for 7 days
Trial: 1547962
Drug: tobramycin (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tobramycin (15 mg/ml) in low-molecular-weight hyaluronic acid applied at 1 drop/h
Trial: 1547962
Drug: tobramycin (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tobramycin (15 mg/ml) in saline applied at 1 drop/h
Trial: 3873582
Drug: Oxygenated crystalloid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygenated crystalloid solution
Trial: 3873582
Drug: Oxygenated solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygenated solution
Trial: 30612946
Drug: Letrozole 2.5
RxNorm normalized name: letrozole 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letrozole 2.5 mg once daily for 6 months
Trial: 30612946
Drug: Low-dose testosterone
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose testosterone (about 1 mg/kg bodyweight) intramuscular injections every 4 weeks for 6 months
Trial: 21490523
Drug: Epidural analgesia
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural analgesia (0.25% levobupivacaine and 30 μg/kg morphine)
Trial: 21490523
Drug: Paravertebral block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paravertebral block (0.5% levobupivacaine and 30 μg/kg morphine)
Trial: 19679747
Drug: Quercetin supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quercetin supplementation (1 g/day for 7-16 days)
Trial: 15010071
Drug: Chemotherapy patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy patients
Trial: 15010071
Drug: Chemotherapy patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy patients with elevated PAI-1
Trial: 9670603
Drug: CARL therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CARL therapy program (computerized exposure therapy)
Trial: 7873699
Drug: CS+ (sherbet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CS+ (sherbet sweet/white noise) paired with epinephrine injection (0.2 mg subcutaneously)
Trial: 28164268
Drug: Supraclavicular block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supraclavicular block with 20 ml of 0.375% ropivacaine
Trial: 28164268
Drug: Interscalene block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interscalene block with 20 ml of 0.375% ropivacaine
Trial: 22556209
Drug: Daily feeding
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily feeding supplementation with a multispecies probiotic (1 g per day)
Trial: 21632815
Drug: Exenatide (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exenatide (10 μg, single sc injection)
Trial: 18823693
Drug: Immediate endocrine
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate endocrine treatment (ET) consisting of a depot luteinising hormone-releasing hormone (LHRH) agonist and 1 month of an anti-androgen or surgical castration.
Trial: 18823693
Drug: Delayed endocrine
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed endocrine treatment (ET) consisting of a depot luteinising hormone-releasing hormone (LHRH) agonist and 1 month of an anti-androgen or surgical castration.
Trial: 18823693
Drug: Delayed endocrine
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed endocrine treatment (ET)
Trial: 18823693
Drug: Immediate endocrine
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate endocrine treatment (ET)
Trial: 17167925
Drug: Other protease
RxNorm normalized name: protease
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other protease inhibitors
Trial: 14516301
Drug: Educational intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Educational intervention with monthly audit sessions and outcome feedback for malaria treatment.
Trial: 14516301
Drug: Educational intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Educational intervention with monthly audit sessions and outcome feedback for diarrhoea treatment.
Trial: 14516301
Drug: Educational intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Educational intervention with monthly audit sessions and outcome feedback for pneumonia treatment.
Trial: 11079651
Drug: Orbufiban 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orbufiban 30 mg, 40 mg, or 50 mg twice daily or 50 mg once daily
Trial: 8932852
Drug: Hib-diphtheria toxoid
RxNorm normalized name: DIPHTHERIA TOXOID
DrugBank: Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (DB10584)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hib-diphtheria toxoid conjugate vaccine (PRP-D) at 6 months and pneumococcal polysaccharide vaccine (Pnc PS) at 8 months
Trial: 8932852
Drug: Pneumococcal polysaccharide
RxNorm normalized name: pneumococcal polysaccharides (23)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pneumococcal polysaccharide vaccine (Pnc PS) at 18 months and Hib-diphtheria toxoid conjugate vaccine (PRP-D) at 20 months
Trial: 1446399
Drug: Propofol 2.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 2.3 mg/kgr
Trial: 1446399
Drug: Thiopental 4.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiopental 4.4 mg/kgr
Trial: 3997307
Drug: Carbamazepine tablets
RxNorm normalized name: Carbamazepine Tablets
DrugBank: Carbamazepine (DB00564)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carbamazepine tablets with rapid absorption
Trial: 3997307
Drug: Carbamazepine tablets
RxNorm normalized name: Carbamazepine Tablets
DrugBank: Carbamazepine (DB00564)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carbamazepine tablets with slow absorption
Trial: 3997307
Drug: All carbamazepine
RxNorm normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All carbamazepine tablets
Trial: 29370819
Drug: FF/VI +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FF/VI + UMEC 100/25 μg + 62.5 μg
Trial: 24828020
Drug: RO-151 200
RxNorm normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RO-151 200 mg
Trial: 24828020
Drug: RO-838 200
RxNorm normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RO-838 200 mg
Trial: 24828020
Drug: RO-151 5
RxNorm normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RO-151 5 mg
Trial: 24828020
Drug: RO-838 50
RxNorm normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RO-838 50 mg
Trial: 18757193
Drug: Increasing maximum
RxNorm normalized name: Maximum-H
DrugBank: Hydrocortisone (DB00741)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Increasing maximum whole breast irradiation (WBI) dose
Trial: 10065579
Drug: Ranitidine 300
RxNorm normalized name: ranitidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine 300 mg orally
Trial: 7307478
Drug: Holistic health
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Holistic health therapy plus family therapy for 10 weeks
Trial: 29627312
Drug: Heliox (79:21)
RxNorm normalized name: Helixate
DrugBank: Helium (DB09155)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Heliox (79:21) delivered via low flow nasal cannula at 2 L/min for 24 hours
Trial: 29627312
Drug: Air delivered
RxNorm normalized name: air
DrugBank: Medical air (DB09337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Air delivered via nasal cannula at 2 L/min for 24 hours
Trial: 28634710
Drug: Vuse Solo
RxNorm normalized name: Fallback Solo
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Vuse Solo (14 to 36 mg nicotine)
Trial: 25370595
Drug: Methylprednisolone (MP)
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (MP) 32 mg/day orally for 7 days
Trial: 23163959
Drug: Olopatadine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olopatadine (5 mg b.i.d.)
Trial: 19455296
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (interpersonal psychotherapy plus medication)
Trial: 15554350
Drug: Fenofibrate 200
RxNorm normalized name: fenofibrate 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenofibrate 200 mg/day for 3 months
Trial: 8301447
Drug: Haemophilus capsular
RxNorm normalized name: Haemophilus capsular oligosaccharide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haemophilus capsular polysaccharide‐tetanus toxoid conjugate (PRP‐T) and diphtheria‐tetanus‐pertussis (DTP) vaccines administered in a single syringe (group 1)
Trial: 8301447
Drug: Haemophilus capsular
RxNorm normalized name: Haemophilus capsular oligosaccharide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haemophilus capsular polysaccharide‐tetanus toxoid conjugate (PRP‐T) and diphtheria‐tetanus‐pertussis (DTP) vaccines administered in separate syringes (group 2)
Trial: 8301447
Drug: PRP‐T vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRP‐T vaccine (group 1)
Trial: 8301447
Drug: PRP‐T vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRP‐T vaccine (group 2)
Trial: 4174488
Drug: Long-term anticoagulant
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term anticoagulant therapy for one year
Trial: 4174488
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no long-term anticoagulant therapy)
Trial: 31489525
Drug: Biobran/MGN-3 (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biobran/MGN-3 (250 mg/day for 3 months)
Trial: 24858657
Drug: Beetroot juice
RxNorm normalized name: tamarind juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beetroot juice (nitrate content 7.5 mmol per 250 ml)
Trial: 24858657
Drug: Placebo (nitrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (nitrate depleted beetroot juice, nitrate content 0.002 mmol per 250 ml)
Trial: 19056592
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg liquid DHA